For patients and families affected by fibrolamellar cancer (FLC), hope is built through progress. Every discovery, every research collaboration, and every clinical trial brings us closer to better treatments for this devastating disease.

Today, that progress is becoming increasingly tangible. Researchers are translating laboratory discoveries into clinical trials that offer new treatment opportunities for people with FLC. One example is a novel four-part immunotherapy being evaluated at Johns Hopkins that combines a peptide vaccine, checkpoint inhibition, and glutamine blockade. By targeting the cancer through multiple complementary mechanisms, investigators hope to generate stronger and more durable anti-tumor responses. Efforts like this demonstrate how promising science can be transformed into potential new therapies.

Your support makes this possible.

Please help accelerate the next breakthrough. Because the Chuck and Marna Davis cover FCF’s operational expenses, 100% of every gift supports fibrolamellar research, helping advance new therapies and treatment opportunities for patients who cannot wait. In addition, the Davis family will match every donation to FCF’s general donation fund received by September 21, 2026, doubling your impact.

Join us in creating more treatment ideas, more clinical trials, and more reasons for hope.

Please click here to make a tax-deductible gift today. Thank you!